Sanofi Takes a $120M Hit as Potential Dengue Vaccine Blockbuster Dealt Safety Blow Post author:Sam Post published:November 29, 2017 Post category:BioPharma Sanofi’s setback could open the door for rival drugmaker Takeda. Source: BioSpace You Might Also Like Why This Tiny Biotech is Giving Cash to Amgen Researchers August 30, 2017 3 Drugs That Could Make-or-Break AbbVie February 11, 2018 The Number 1 Small-Cap Biotech Investors are Missing Out On December 26, 2017
